Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZNTL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZentalis presents preclinical data on azenosertib at AACR cancer research conference
Filed April 17, 2026 · Period ending April 17, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release and presented two research posters at the American Association for Cancer Research Annual Meeting in San Diego, April 17-22, 2026.
Item 7.01 verify on EDGAR → -
medium
Preclinical poster evaluated azenosertib, a WEE1 inhibitor, as single agent and in combination for triple-negative breast cancer treatment.
Exhibit 99.2 view on EDGAR → -
low
Second poster presented real-world treatment patterns and outcomes for patients with cyclin E1-positive ovarian cancer, a biomarker relevant to Zentalis's therapeutic focus.
Exhibit 99.3 view on EDGAR →
Summary
Zentalis Pharmaceuticals disclosed preclinical research findings at a major cancer research conference. The company presented data on azenosertib, one of its pipeline drug candidates targeting WEE1, showing activity in triple-negative breast cancer models both alone and in combination therapies. A second presentation shared real-world clinical data on cyclin E1-positive ovarian cancer patients, providing market context for the company's development programs.
For retail investors, this is a routine scientific disclosure typical of biotech companies advancing drug candidates through development. Conference presentations help establish scientific credibility and can attract partnership interest, but preclinical data is early-stage and doesn't guarantee clinical success. Watch for any follow-up announcements about clinical trial initiations or data readouts for azenosertib, which would represent more material pipeline progress than conference posters.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 17, 2026, Zentalis Pharmaceuticals, Inc ("Zentalis" or the "Company") issued the press released furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report") and incorporated herein by reference.
Zentalis issued a press release on April 17, 2026. The specific content of the press release is provided in Exhibit 99.1, which is not included in this 8-K body text. This is a Regulation FD disclosure, meaning the company is publicly disclosing information to ensure fair access to all investors.
Added in current filing · verify on EDGAR →
Additionally, the Company is presenting the posters furnished as Exhibits 99.2 and 99.3 to this Current Report and incorporated herein by reference at the 2026 American Association for Cancer Research ("AACR") Annual Meeting taking place April 17-22, 2026, in San Diego, CA.
Zentalis is presenting two research posters at the AACR Annual Meeting from April 17-22, 2026 in San Diego. AACR is a major cancer research conference, and poster presentations typically share clinical trial data or preclinical research findings. The actual poster content is in Exhibits 99.2 and 99.3, which are not included in this 8-K body.
Event · Item 9.01 — Financial Statements and Exhibits
Zentalis filed an 8-K to furnish a press release and two AACR conference posters on preclinical and real-world data for its drug candidates.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
AACR poster titled "WEE1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer: Evaluating Single Agent and Combination Activity of Azenosertib in Preclinical Models"
Zentalis disclosed preclinical research on azenosertib, a WEE1 inhibitor, evaluating its activity alone and in combination in triple-negative breast cancer models. This represents ongoing scientific development of the company's pipeline candidate.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify